For more than 70 years, the Sloan Kettering Institute has set the pace for cancer science.
The Sloan Kettering Institute (SKI) is the experimental research arm of Memorial Sloan Kettering Cancer Center. Discoveries made in SKI labs are an important driver of clinical progress at MSK and beyond. Our research spans nine program areas:
MSK Science Spotlight
In this time of a global pandemic, relying on science to help us make decisions is more important than ever. Memorial Sloan Kettering is proud to announce MSK Science Spotlight, a twice-weekly scientific seminar series featuring illuminating lectures by today’s leaders in basic and translational biomedical science. Seminars are viewable via livestream every Monday and Wednesday at 4:30 pm ET. No registration is required. Seminars last 60 minutes, including 15 minutes for Q & A.
- June 3: David Solit, MD
- June 8: Jason Lewis, PhD
- June 11: Winners of the Tri-Institutional Breakout Prize for Junior Investigators
- June 15: Derek Tan, PhD
- June 17: Stephen B. Long, PhD
- June 22: Alexandra Joyner, PhD
- June 29: Yael David, PhD
- July 8: Kravis Women in Science Endeavor (WiSE) Fellowship Winners
- July 13: Akiko Iwasaki, PhD
- July 15: Ashani Weeraratna, PhD
- July 20: Viviane Tabar, MD
- July 27: Alexander Rudensky, PhD
- July 29: Joan Massagué, PhD
Discover how we do cancer science.
A Collaborative Approach
Collaboration is a hallmark of the research enterprise at SKI. Our scientists collaborate across programs, across disciplines, and across institutions.
Collaborative Research Centers
Researchers from SKI and Memorial Hospital join forces in 23 established Collaborative Research Centers. These innovative centers bring together laboratory scientists and clinicians to spark innovation.
Joint Graduate Programs
SKI enjoys close relationships with neighbors Rockefeller University and Weill Cornell Medicine, and partners with them in several joint graduate programs.
Tri-Institutional Therapeutics Discovery Institute
This innovative partnership between MSK, Rockefeller, Weill Cornell, and industry aims to speed the translation of basic scientific discoveries into promising new medicines.